Surprisingly versatile in Type 1 diabetes care, Sanofi’s Tzield reshapes the early stage

Tzield from Sanofi is the first FDA-approved therapy to delay stage 3 Type 1 diabetes in at-risk children and adults. We outline how the drug is used, which patients qualify, and why it matters for the French pharma group’s immunology pipeline.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 7:16 PM ET. Details in the imprint.

With its humanized anti-CD3 antibody Tzield (teplizumab-mzwv), Sanofi has put a distinctive marker in Type 1 diabetes care: the drug is the first therapy approved by the US Food and Drug Administration (FDA) to delay the onset of stage 3 Type 1 diabetes in patients at high risk. The monoclonal antibody is targeted at children and adults with stage 2 disease and aims to preserve beta-cell function long enough to push back the need for full insulin replacement.

The FDA initially cleared Tzield in 2022 for patients 8 years and older with stage 2 Type 1 diabetes who have two or more autoantibodies and dysglycemia, and Sanofi has since expanded its label to include adults, broadening the eligible population in the US. According to the company, the pivotal TN-10 trial showed that a single 14-day course of Tzield roughly doubled the median time to progression from stage 2 to stage 3 Type 1 diabetes compared with placebo, translating into several additional years without overt disease for many patients. These data underpin the drug’s positioning as a disease-modifying intervention, rather than just another tool for glucose control.

How Tzield works, who it is for, and how it is given

Mechanistically, Tzield targets the CD3 receptor on T cells, a key component of the adaptive immune system, with the goal of modulating the autoimmune attack on pancreatic beta cells that drives Type 1 diabetes. In the TN-10 study, investigators observed that patients receiving teplizumab experienced a rebalancing of T-cell subsets and a relative preservation of C-peptide levels, a marker of endogenous insulin secretion, which correlated with the delayed progression to clinical disease. Sanofi and its partner emphasize that this is not a cure, but a temporary reprieve in a chronic autoimmune process.

In routine practice, Tzield is administered as a series of once-daily intravenous infusions over 14 consecutive days in an outpatient setting. Dosing is weight-based and escalates over the first few days to mitigate cytokine release-related symptoms such as fever or rash, which are among the most commonly reported adverse reactions. Patients must be monitored for lymphopenia, infections and liver enzyme changes during treatment, and the prescribing information includes guidance on interrupting or discontinuing infusions if laboratory parameters fall outside defined ranges. The regimen is intensive for families, but it is finite, which differentiates Tzield from chronic biologic therapies used in other autoimmune diseases.

Eligibility is another critical piece. Tzield is indicated in the US for adults and children 8 years and older with stage 2 Type 1 diabetes, meaning they have at least two pancreatic autoantibodies and evidence of dysglycemia on an oral glucose tolerance test while still being asymptomatic. That positioning presupposes access to screening programs that can identify at-risk individuals before they present with diabetic ketoacidosis or marked hyperglycemia. Sanofi has therefore highlighted collaborations with screening initiatives and foundations to raise awareness of early testing in relatives of patients with Type 1 diabetes, an effort that could expand the pool of patients who can benefit from a course of Tzield.

From a pricing and reimbursement standpoint, Tzield is positioned as a specialty biologic. US list prices are high compared with conventional insulin therapies, and access typically runs through prior authorization pathways in commercial plans and selected government programs. Economic analyses discussed by diabetes specialists point out that avoiding or delaying full-blown Type 1 diabetes can reduce hospitalizations and long-term complications, providing a potential offset to the upfront cost for payers. However, real-world cost-effectiveness will heavily depend on how consistently screening and early diagnosis are implemented in clinical practice, a factor that differs markedly between health systems.

Tzield also fits into Sanofi’s broader strategy to expand its immunology portfolio beyond its blockbuster Dupixent. The company has underscored that the launch gives it a foothold in disease-modifying therapies in endocrinology and opens the door to further CD3-based or T-cell-targeted approaches in other autoimmune indications. The French drugmaker acquired the original developer Provention Bio in 2023 to secure full rights to teplizumab, and it has been investing in post-approval studies to refine dosing strategies, evaluate repeat courses, and assess the impact of treatment at different ages and risk profiles. That evidence base will likely determine how widely endocrinologists and pediatric diabetologists adopt Tzield in routine care.

Regulators and professional societies are watching the roll-out closely, not least because Tzield has shifted the discussion from managing established Type 1 diabetes to proactively delaying its onset. Diabetes advocacy groups have welcomed the prospect of giving children and families extra years without daily insulin injections and continuous glucose monitoring, even if the effect is time-limited. At the same time, bioethics experts point to the need for robust counseling: families must weigh the potential benefits of a 14-day immunotherapy course against the risks of immune modulation in otherwise asymptomatic children who might not develop overt diabetes for several years.

Sanofi’s communications emphasize that Tzield’s current approval is limited to the US, and the company is working with other regulators to define the data requirements for potential filings in additional markets. For investors, the drug is not yet a material revenue contributor on the scale of Sanofi’s leading products, but it is viewed as an important strategic asset in the company’s immunology and rare disease portfolio. Shares of Sanofi (ISIN FR0000120578) trade on Euronext Paris, where the group is part of the CAC 40; its performance is influenced by expectations for newer launches such as Tzield alongside established franchises.

Tzield in brief: key facts for patients and investors

• Product: Tzield (teplizumab-mzwv)
• Manufacturer: Sanofi S.A.
• Category: Flagship disease-modifying biologic
• Launch date: Initial US approval in 2022 for stage 2 Type 1 diabetes (label later expanded to adults)
• MSRP / Price: Specialty biologic pricing; reimbursed through US insurers and selected government programs where covered
• Availability: Currently marketed in the United States; further regulatory filings under consideration
• Target audience: Children and adults 8 years and older with stage 2 Type 1 diabetes at high risk of progression
• Key differentiator / USP: First FDA-approved therapy to delay the onset of stage 3 Type 1 diabetes in at-risk individuals

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.